您的位置: 首页 > 农业专利 > 详情页

Imiquimod formulations with lower dosage concentration and short dosage regimens for the treatment of actinic keratosis.
专利权人:
LLC;GRACEWAY PHARMACEUTICALS
发明人:
JAMES H. KULP,JAMES H. LEE,JASON J. WU,KODUMUDI S. BALAJI,MCHAEL T. NORDSIEK,ROBERT BABILON,SHARON F. LEVY,TZE-CHIANG MENG,VALYN S. BAHM
申请号:
BRPI0923164
公开号:
BRPI0923164A2
申请日:
2009.12.11
申请国别(地区):
BR
年份:
2016
代理人:
摘要:
Pharmaceutical formulations and methods for the topical or transdermal delivery of 1-isobutyl-1H-imidazo[4,5-c]-quinolin-4-amine or 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine, i.e., imiquimod, to treat actinic keratosis with short durations of therapy, than currently prescribed for the commercially available Aldara® 5% imiquimod cream, as now approved by the U.S. Food & Drug Administration (“FDA”), are disclosed and described. More specifically, lower dosage strength imiquimod formulations to deliver an efficacious dose of imiquimod for treating actinic keratosis with an acceptable safety profile and dosing regimens that are short and more convenient for patient use than the dosing regimen currently approved by the U.S. Food & Drug Administration (“FDA”) for Aldara® 5% imiquimod cream to treat actinic keratosis are also disclosed and described.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充